

IN THE CLAIMS:

1. (Canceled)
2. (Currently amended) The ~~medicament~~ method as claimed in claim [[1]] 8, characterized in that xenon is present in a pharmacologically effective amount.
3. (Currently amended) The ~~medicament~~ method as claimed in claim [[1]] 8, characterized in that the ~~medicament~~ preparation for cerebral protection further comprises ~~as remainder oxygen~~ or oxygen and an inert gas.
4. (Currently amended) The ~~medicament~~ method as claimed in claim [[1]] 8, characterized in that the ~~medicament~~ preparation is used as a combination product with a gaseous, liquid or solid preparation comprising an NO source, for simultaneous, separate or sequential use.
5. (Currently amended) ~~A medicament, comprising xenon according to claim 1 and an NO source or a xenon-containing gas mixture and an NO source;~~ The method as claimed in claim 9 where xenon and the NO source are present in pharmacologically effective ~~concentration~~ concentrations.
6. (Currently amended) ~~The use of xenon or of a xenon-containing gas mixture and, where appropriate, of an NO source to produce a medicament for~~ method as claimed in claim 8, wherein the preparation is used for a condition selected from the group consisting of the treatment of impairments of blood flow in the brain, ~~to produce a medicament for the treatment of impairment of cerebral perfusion, to produce a medicament for the treatment of cognitive impairments, to produce a medicament for cerebral protection, to produce a medicament for the prophylaxis and/or therapy of impairments of cognitive performance[.]~~ and also postoperatively,

~~to produce a medicament for the treatment of stroke, to produce a medicament for the~~
prophylaxis of stroke, ~~to produce a medicament for improving the oxygen supply in the brain, to~~
~~produce a medicament for the treatment of post-ischemia syndrome, to produce a medicament~~
~~for promoting blood flow in the brain, to produce a medicament for the treatment or prophylaxis~~
of ~~pastoperative~~ postoperative cognitive dysfunction ~~or to produce a medicament for , and~~
cerebral vasodilatation.

7. (Currently amended) ~~The use of xenon or of a xenon-containing gas mixture and, where~~
~~appropriate, of an NO source for~~ method as claimed in claim 8, wherein the preparation is used
for a condition selected from the group consisting of cerebral protection, for cerebral
vasodilatation ~~or for , and~~ the treatment, therapy or prophylaxis of impairments of cognitive
performance or cognitive dysfunction.

8. (New) A method for cerebral protection, wherein a preparation is made which comprises
xenon in the form of xenon or a xenon-containing gas mixture, and the preparation is
administered to a patient in need of such preparation.

9. (New) The method as claimed in claim 8, wherein the preparation further comprises an
NO source.

10. (New) The method as claimed in claim 8, characterized in that the preparation further
comprises oxygen.

11. (New) The method as claimed in claim 8, characterized in that the preparation consists of
xenon.

12. (New) The method as claimed in claim 8, characterized in that the preparation consists of
xenon and an NO source.

13. (New) The method as claimed in claim 8, characterized in that the preparation consists of xenon and oxygen.
14. (New) The method as claimed in claim 8, characterized in that the preparation consists of xenon, oxygen and an inert gas.
15. (New) The method as claimed in claim 6, wherein an NO source is included in the preparation.
16. (New) The method as claimed in claim 7, wherein an NO source is included in the preparation.